- Conditions
- EGFR Gene Mutation, Nonsmall Cell Lung Cancer
- Interventions
- Dasatinib, Osimertinib
- Drug
- Lead sponsor
- Chul Kim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Interventions
- Asciminib (ABL001), Nilotinib, Imatinib, Dasatinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- RO7283420, Tocilizumab, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Sacramento, California • Houston, Texas
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Dasatinib, Dasatinib Maximum Tolerated Dose
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Advanced Cancer
- Interventions
- Dasatinib, Bevacizumab, Paclitaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
- Interventions
- Dasatinib, Ganitumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Bethesda, Maryland